Clinical Trial Update: Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Fanhdi, a high-purity von Willebrand factor-containing FVIII concentrate, to assess efficacy and safety in pediatric patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Fanhdi

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Von Willebrand Disease | Phase 4 | Status: RECRUITING